SOTIO Biotech Collaborates with Biocytogen for Expanding ADC Pipeline
Shots:
- SOTIO Biotech has entered into a research collaboration and exclusive option & license agreement with Biocytogen for expanding its ADC pipeline
- As per the agreement, SOTIO gets the option to employ Biocytogen’s ADC platform & license human bispecific Abs from Biocytogen’s RenLite platform to advance them as ADCs for solid tumors. It will further handle their preclinical & clinical activities, manufacturing as well as commercialization
- Biocytogen will obtain a total of ~$325.5M as upfront & milestones along with low single-digit royalties. Both companies will work closely during the bispecific programs' R&D phase
Ref: SOTIO Biotech | Image: SOTIO Biotech & Biocytogen
Related News: Nona Biosciences Partners with Alaya.bio to Advance CAR-T Cell Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
